Sign in

    Azenta Inc (AZTA)

    Q4 2024 Earnings Summary

    Reported on Feb 20, 2025 (After Market Close)
    Pre-Earnings Price$45.99Last close (Nov 12, 2024)
    Post-Earnings Price$47.86Open (Nov 13, 2024)
    Price Change
    $1.87(+4.07%)

    What went well

    • Strong Growth in Next-Generation Sequencing (NGS) Segment: Azenta's NGS business grew 25% year-over-year in the fourth quarter, driven by increased volumes and price stabilization. This robust growth indicates positive momentum heading into fiscal year 2025. ,
    • Margin Expansion with Confidence in Achieving Long-Term Targets: The company achieved 300 basis points of adjusted EBITDA margin expansion in fiscal year 2024, resulting in margins above 11%. Azenta is confident in achieving an EBITDA margin of 15% to 17% by fiscal year 2026, highlighting strong operational efficiencies and cost optimization initiatives. ,
    • Competitive Advantage in Automated Storage Solutions: Despite a decline in stores revenue due to tough comparables, Azenta has 75% visibility into the backlog for its storage business and is bullish on the shift towards automated storage solutions. The company believes it has unique capabilities and competitive advantages in this high-growth area, which could drive significant future growth.

    What went wrong

    • Azenta's guidance for fiscal year 2025 is 3% to 5% organic revenue growth, which is lower than previous expectations. Management acknowledges that they have "struggled on the top line" and there is uncertainty in the market, indicating potential challenges in achieving growth targets.
    • The company is experiencing sales force turnover and open territories, with potential for distraction due to ongoing transformation efforts, which could impact execution and sales performance.
    • While Next-Generation Sequencing (NGS) grew 25% in the quarter, management is cautious about the sustainability of this growth, stating "We don't want to count on that trend right now as continuing", suggesting that future NGS growth may not match recent strong performance.

    Q&A Summary

    1. Guidance and Targets Achievability
      Q: Are fiscal '26 targets achievable excluding B Medical?
      A: Management believes the fiscal '26 targets, including 15‒17% EBITDA margin, are achievable even after excluding B Medical. The guidance of 3‒5% organic growth for fiscal '25 accounts for the current market environment, and if recovery comes in the second half of 2025, there could be upside.

    2. EBITDA Margin Outlook
      Q: Is the fiscal '25 EBITDA margin guidance flattish due to B Medical exit?
      A: While recent quarters showed EBITDA margins above 10%, management is guiding conservatively due to necessary investments in fiscal '25. They expect 300 basis points of EBITDA margin expansion each year and remain confident in achieving the 15‒17% EBITDA margin target by fiscal '26.

    3. B Medical Divestiture Timing
      Q: When will the B Medical transaction close?
      A: Management expects the B Medical divestiture to close in the first half of the year, certainly within one year, allowing focus on high-margin businesses.

    4. China Performance and Tariff Impact
      Q: How did China perform, and are tariffs a concern?
      A: China revenue grew 10% in Q4 and 12% for fiscal '24. Management does not anticipate tariff impacts, as they manufacture regionally—serving China from China and the U.S. from the U.S.

    5. NGS Growth and Pricing Trends
      Q: What are the trends in NGS pricing and volume?
      A: NGS revenues grew 25% in the quarter, driven by increased volume and price stabilization from Q3 to Q4. Management remains cautious on pricing trends but notes positive momentum entering fiscal '25.

    6. Stores Business Outlook
      Q: Why were stores down, and what's the outlook?
      A: Stores were down due to a tough comparison with a record growth quarter in fiscal '23. With 75% visibility into the backlog, management is confident in their fiscal '25 guidance. They see a market shift toward automated storage solutions and are bullish on their capabilities.

    7. Capital Allocation and M&A Strategy
      Q: What's the M&A strategy and capital allocation focus?
      A: The company emphasizes portfolio optimization, operational excellence, and disciplined capital allocation. M&A targets must meet stringent double-digit ROIC criteria. They're interested in strategic tuck-ins, especially in the SMS business and biorepositories, aiming to enhance automation and margins.

    8. CapEx Expectations Post-Divestiture
      Q: Will CapEx trend lower after B Medical sale?
      A: CapEx may decrease but is expected to remain within 4–6% of sales. Management is reviewing capital deployment to align with strategic initiatives, focusing on productivity and growth opportunities.

    9. EBITDA Margin Expansion Basis
      Q: Is the 300 bps margin expansion on an apples-to-apples basis?
      A: Yes, the 300 basis points of EBITDA margin expansion is calculated on a comparable basis for the remaining company after B Medical's divestiture. Recast financials will be provided for clarity.

    10. Pricing Headwinds in NGS
      Q: Are pricing headwinds in NGS expected to continue?
      A: Management anticipates continued pricing headwinds in NGS for 2025 but is cautious about declaring a trend after one quarter of price stabilization.

    Related Publications